Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Irwin Walker, Uday Deotare, Mohamed Elemary, Mahmoud Elsawy, Genevieve Gallagher, David Kliman, Tony Panzarella, Nada Hamad, Kirk R. Schultz, Jan Storek, Kristjan Paulson

Blood (2024) 144 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2024-198798

Published: 2024

Journal Articles

Quality of Life and Comorbidities of Adult Survivors of Allogeneic Hematopoietic Cell Transplant Versus Their Siblings

Nikki Blosser, Sunita Ghosh, Bhavi Desai, Nicole Crisp, Baljit Randhawa, Grace Beda, Andrew Daly, Jan Storek, Kareem Jamani

Blood (2023) 142 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2023-190789

Published: 2023

Journal Articles

The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis

Ayman Sayyed, Hyewon Lee, Taehyung Simon Kim, Jaeyoon John Kim, Danielle Pyne, Nathali Kaushansky, Yardena Brilon, Noa Chapal-Ilani, Tamir Biezuner, Liran I. Shlush, Jan Storek, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2023-191191

Published: 2023

Journal Articles

Pharmacokinetic-Targeting and Dose-Adjustment of I.V. Busulfan for Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation

Rutvij A. Khanolkar, Shahbal B Kangarloo, Na Li, Faisal Khan, Jan Storek

Blood (2023) 142 (Supplement 1): 6980.

https://doi.org/10.1182/blood-2023-190089

Published: 2023

Journal Articles

Proinflammatory Cytokine Release and Infusional Side-Effects after Anti-Thymocyte Globulin Serotherapy for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

Rutvij A. Khanolkar, Stephanie Dookie, Na Li, Faisal Khan, Jan Storek

Blood (2023) 142 (Supplement 1): 6782.

https://doi.org/10.1182/blood-2023-189653

Published: 2023

Journal Articles

The KIR-HLA-CD16a Immunogenetic Profile Influences NK Cell-Mediated ADCC and Response to Rituximab Therapy in B-Cell Lymphomas

Rutvij A. Khanolkar, Ariz Akhter, Jan Storek, Faisal Khan

Blood (2023) 142 (Supplement 1): 5796.

https://doi.org/10.1182/blood-2023-190062

Published: 2023

Journal Articles

Chimerism of Blood T-Cells and Leukemia Lineage Cells Following Myeloablative Hematopoietic Cell Transplantation Is a Risk Factor for Relapse and Chronic Graft-Versus-Host Disease

Rutvij A. Khanolkar, Poonam Dharmani-Khan, Faisal M Khan, Jan Storek

Blood (2021) 138 (Supplement 1): 4887.

https://doi.org/10.1182/blood-2021-148144

Published: 2021

Journal Articles

Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study

Jaime Sanz, Jan Storek, Gérard Socié, Dhanalakshmi Thirumalai, Norma Guzman-Becerra, Pengcheng Xun, Deepali Kumar, Natalia Sadetsky, Daan Dierickx, John Reitan, Arie Barlev, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 1454.

https://doi.org/10.1182/blood-2021-147296

Published: 2021

Journal Articles

Early Prediction of Moderate-Severe Chronic GvHD By Immunity Related Transcriptome

Amit Kalra, MBBS, MSc, Poonam Dharmani-Khan, PhD, Stuti Patel, BHSc, Rehan Mujeeb Faridi, PhD, Victor A. Lewis, MD, Andrew Daly, MD, Adnan Mansoor, MDPhD, Meer-Taher Shabani-Rad, MD, Jan Storek, MD PhD, Faisal M Khan, PhD D (ABHI)

Blood (2018) 132 (Supplement 1): 70.

https://doi.org/10.1182/blood-2018-99-119926

Published: 2018

Journal Articles

High Pre-HCT Exposure to Thymoglobulin Is Associated with a Low Incidence of Relapse

Rosy Dabas, BSc, MSc, Kareem Jamani, MD, Bill Kangarloo, M.Sc, Poonam Dharmani-Khan, PhD, Don Morris, MD PhD FRCPC, Douglas Mahoney, PhD, Andrew Daly, MD, Faisal M Khan, PhD D (ABHI), Jan Storek, MD PhD

Blood (2018) 132 (Supplement 1): 4605.

https://doi.org/10.1182/blood-2018-99-117332

Published: 2018

Journal Articles

Intermediate Post-HCT Exposure to Thymoglobulin Minimizes Mortality and High Exposure Minimizes the Composite of Death, Relapse or Chronic Graft-Versus-Host Disease

Kareem Jamani, MD, Rosy Dabas, BSc, MSc, Poonam Dharmani-Khan, PhD, Andrew Daly, MD, Jan Storek, MD PhD

Blood (2017) 130 (Supplement 1): 3245.

https://doi.org/10.1182/blood.V130.Suppl_1.3245.3245

Published: 2017

Journal Articles

Rabbit Anti-Thymocyte Globulin Kills Leukemic Stem Cells to a Greater Degree Than Healthy Hematopoietic Stem Cells

Rosy Dabas, BSc, MSc, Poonam Dharmani-Khan, PhD, Monica Modi, MD, Tiffany Van Slyke, MD, Joanne Luider, BSc, ART, MLT, Joseph M. Brandwein, MD FRCPC, Don Morris, MD PhD FRCPC, Andrew Daly, MD, Faisal M Khan, PhD D (ABHI), Jan Storek, MD PhD

Blood (2017) 130 (Supplement 1): 5511.

https://doi.org/10.1182/blood.V130.Suppl_1.5511.5511

Published: 2017

Journal Articles

Prediction of Severe Acute Graft-Versus-Host Disease (aGVHD) Based on Whole Transcriptome Sequencing of Donor CD4 T Cells

Silvy Lachance, MDFRCPC, Jonathan Séguin, MSc., Ann Brasey, PhD, Jean-Philippe Laverdure, PhD, Vincent T Ho, MD, Jerome Ritz, MD, Jan Storek, MD PhD, Denis-Claude Roy, MD, Lambert Busque, MD, Sébastien Lemieux, PhD, Claude Perreault, MD

Blood (2017) 130 (Supplement 1): 3249.

https://doi.org/10.1182/blood.V130.Suppl_1.3249.3249

Published: 2017

Journal Articles

Anti-Thymocyte Globulin Kills Leukemic Stem Cells in Vitro

Rosy Dabas, M.Sc., B.Sc., Poonam Dharmani, PhD, Monica Modi, MD, Tiffany Van Slyke, Joanne Luider, Joseph M. Brandwein, MD FRCPC, Don Morris, Andrew Daly, MD FRCPC, Faisal M Khan, PhD D (ABHI), Jan Storek, MD PhD

Blood (2016) 128 (22): 4616.

https://doi.org/10.1182/blood.V128.22.4616.4616

Published: 2016

Journal Articles

Differential Expression of Immunity Related Genes and Early Prediction of Severe Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation

Poonam Dharmani-Khan, PhD, Rehan Mujeeb Faridi, PhD, Ariz Akhter, PhD, Amit Kalra, MBBS, MS, Jan Storek, MD PhD, Faisal M Khan, PhD D (ABHI)

Blood (2016) 128 (22): 4576.

https://doi.org/10.1182/blood.V128.22.4576.4576

Published: 2016

Journal Articles

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Blood (2016) 127 (24): 3082–3091.

https://doi.org/10.1182/blood-2015-09-668251

Published: 2016

Includes: Supplemental data

Journal Articles

Limited Efficacy of Prompt Therapy of Posttransplant Lymphoproliferative Disorder (PTLD) with Rituximab

Amit Kalra, MBBS, MS, Cameron Roessner, BScPharm, Jennifer Jupp, BScPharm,BCOP, Andrew Daly, MD FRCPC, Jan Storek, MD PhD

Blood (2015) 126 (23): 3114.

https://doi.org/10.1182/blood.V126.23.3114.3114

Published: 2015

Journal Articles

Influence of Fludarabine Pharmacokinetics on Outcome of Allogeneic Stem Cell Transplantation with Fludarabine-Busulfan Conditioning

Mita Manna, MD FRCPC, Andrew Daly, MD FRCPC, Bill Kangarloo, Mary Lynn Savoie, MD FRCPC, Jan Storek, MD PhD

Blood (2015) 126 (23): 3119.

https://doi.org/10.1182/blood.V126.23.3119.3119

Published: 2015

Journal Articles

Copies of Donor Killer Immunoglobulin-like Receptor Genes and Motifs Titrate Natural Killer (NK) Cells' Functional Response to Epstein - Barr Virus Infections and Influence the Risk of Developing Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Cell Transplantation

Rehan Mujeeb Faridi, PhD, Taylor J Kemp, B.HSc, Poonam Dharmani, PhD, Victor A. Lewis, MD, Noureddine Berka, PhD D (ABHI), Jan Storek, MD PhD, Faisal M Khan, PhD D (ABHI)

Blood (2015) 126 (23): 741.

https://doi.org/10.1182/blood.V126.23.741.741

Published: 2015

Journal Articles

Cytomegalovirus (CMV) Serostatus: High Importance of Choosing Seropositive Donors for Seropositive Patients When Using Rabbit Antithymocyte Globulin (ATG)

Amit Kalra, MBBS, MS, Andrew Daly, MD FRCPC, Jan Storek, MD PhD

Blood (2015) 126 (23): 4402.

https://doi.org/10.1182/blood.V126.23.4402.4402

Published: 2015

NARROW

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Quality of Life and Comorbidities of Adult Survivors of Allogeneic Hematopoietic Cell Transplant Versus Their Siblings

The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis

Pharmacokinetic-Targeting and Dose-Adjustment of I.V. Busulfan for Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation

Proinflammatory Cytokine Release and Infusional Side-Effects after Anti-Thymocyte Globulin Serotherapy for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

The KIR-HLA-CD16a Immunogenetic Profile Influences NK Cell-Mediated ADCC and Response to Rituximab Therapy in B-Cell Lymphomas

Chimerism of Blood T-Cells and Leukemia Lineage Cells Following Myeloablative Hematopoietic Cell Transplantation Is a Risk Factor for Relapse and Chronic Graft-Versus-Host Disease

Clinical Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study

Early Prediction of Moderate-Severe Chronic GvHD By Immunity Related Transcriptome

High Pre-HCT Exposure to Thymoglobulin Is Associated with a Low Incidence of Relapse

Intermediate Post-HCT Exposure to Thymoglobulin Minimizes Mortality and High Exposure Minimizes the Composite of Death, Relapse or Chronic Graft-Versus-Host Disease

Rabbit Anti-Thymocyte Globulin Kills Leukemic Stem Cells to a Greater Degree Than Healthy Hematopoietic Stem Cells

Prediction of Severe Acute Graft-Versus-Host Disease (aGVHD) Based on Whole Transcriptome Sequencing of Donor CD4 T Cells

Anti-Thymocyte Globulin Kills Leukemic Stem Cells in Vitro

Differential Expression of Immunity Related Genes and Early Prediction of Severe Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Limited Efficacy of Prompt Therapy of Posttransplant Lymphoproliferative Disorder (PTLD) with Rituximab

Influence of Fludarabine Pharmacokinetics on Outcome of Allogeneic Stem Cell Transplantation with Fludarabine-Busulfan Conditioning

Copies of Donor Killer Immunoglobulin-like Receptor Genes and Motifs Titrate Natural Killer (NK) Cells' Functional Response to Epstein - Barr Virus Infections and Influence the Risk of Developing Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Cell Transplantation

Cytomegalovirus (CMV) Serostatus: High Importance of Choosing Seropositive Donors for Seropositive Patients When Using Rabbit Antithymocyte Globulin (ATG)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only